| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C21H16ClN3O2 |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
Adaptaquin is a blood-brain-barrier-penetrable inhibitor of HIF prolyl-hydroxylases (HIF-PHDs) with anti-inflammatory and neuroprotective effects. It can effectively inhibit lipid peroxidation, preserve mitochondrial function, and reduce neuronal death, and can be used to study nervous system diseases such as Parkinson's disease[1][2][3]. It is supplied as a white to yellow solid (C21H16ClN3O2, MW 377.82) at 99.87% purity.
Physical & Chemical Properties
| CAS Number | 385786-48-1 |
|---|---|
| Molecular Formula | C21H16ClN3O2 |
| Molecular Weight | 377.82 g/mol |
| Purity | 99.87% |
| Appearance | Solid |
| Color | White to yellow |
| SMILES | OC1=C2N=CC=CC2=CC=C1C(C3=CC=C(Cl)C=C3)NC4=NC=CC=C4O |
| Signaling Pathway | Metabolic Enzyme/Protease; NF-κB; Immunology/Inflammation |
| Solubility | In Vitro: DMSO: 100 mg/mL (264.68 mM; Requires sonication; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 100 mg/mL (264.68 mM) | requires sonication; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
Data provided by the manufacturer.
In Vitro
In glutamate-treated HT-22 cells, Adaptaquin (0.5-5 μM; 4-15 h) can increase viability and inhibit lipid peroxidation and ROS production[1]. At 0.1-5 μM for 24-48 h, Adaptaquin can significantly protect ventral midbrain dopaminergic neurons and PC12 cells against cell death induced by Oxidopamine (6-OHDA) and MPP+, and can maintain cell morphology[2]. Adaptaquin (0.5 μM; 8-16 h) can inhibit 6-OHDA/MPP+-induced expression of Trib3, ATF4, and CHOP, and can maintain Parkin protein levels in PC12 cells[2].
Real Time qPCR[2]
| Cell Line | 6-OHDA/ MPP+ treated PC12 |
|---|---|
| Concentration | 0.5 μM |
| Incubation Time | 8 h/16 h |
| Result | Reduced the mRNA levels of Trib3, ATF4 and CHOP. |
In Vivo
In a mouse model of Parkinson's disease, Adaptaquin (30 mg/kg; intraperitoneal injection; 7 days) has a protective effect[2].
| Animal Model | Adult male C57BL/6 mice (10-12 weeks) treated 6-OHDA hydrobromide[2] |
|---|---|
| Dosage | 30 mg/kg |
| Administration | Intraperitoneal injection; 7 days |
| Result | Enhanced survival of dopaminergic neurons and substantially protected their striatal projections. Significantly enhanced retention of nigrostriatal function. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
Biophysical and biochemical studies support PHD inhibitor development as a TPI deficiency therapy. J Cell Sci 2026 May 1;139(9):jcs264664. PMID: 41949155
Cyberleninka. 2025.
Malmö Universitet. 2023 Jun 26.
